Evidence map›Paper›PMID 42436880›Full record

ArticleBlood neoplasia2026

CD8

Nezar Mehanna, Andriy Derkach, Billel Gasmi, Theodora Anagnostou, Heather J Landau, Oscar B Lahoud, Michael Scordo, Gunjan L Shah, Hani Hassoun, Kylee Maclachlan and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nezar MehannaDepartment of Medicine, Mount Sinai Hospital, New York, NY.
Andriy DerkachDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Billel GasmiSurgery Branch, National Cancer Institute, Bethesda, MD.
Theodora AnagnostouAdult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Heather J LandauAdult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Oscar B LahoudAdult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Michael ScordoAdult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Gunjan L ShahAdult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Hani HassounDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Kylee MaclachlanDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Malin HultcrantzDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Neha KordeDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Sham MailankodyDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Urvi A ShahDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Carlyn R TanDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Saad Z UsmaniAdult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Sergio A GiraltAdult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Alexander M LesokhinDepartment of Medicine, Weill Cornell Medical College, New York, NY.
David J ChungAdult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS P30 CA008748NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660
6 · The paper itself

Abstract

Patients with multiple myeloma (MM) who experience early relapse (ER) within 24 months of autologous stem cell transplantation (ASCT) have inferior overall survival and represent a functionally high-risk (HR) subgroup. To investigate immune features of functionally HR MM, we performed immunohistochemistry (IHC) of the bone marrow and high-dimensional flow cytometry-based phenotyping of peripheral blood to evaluate the T-cell compartment of patients with MM at day 100 after ASCT. An initial IHC-based analysis of a cohort of patients with MM (n = 110) with long-term follow-up implicated CD3

Identifiers

PMID42436880
PMCPMC13355025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.